Wuxi Bio Short-term Analysis: Resistance Test After Rebound, Intensified Tug-of-war Between Bulls and Bears

As of April 1, Wuxi Bio (02269) closed at HKD 34.94, up 5.81%, with a turnover of HKD 1.08 billion. The stock price rebounded significantly after several days of adjustment and regained support above the 10-day moving average (HKD 33.02). However, it remains constrained by the 30-day moving average (HKD 35.97) and the 60-day moving average (HKD 37.01), indicating that although there are signs of a short-term rebound from the bottom, the medium-term trend has not reversed yet. From a technical perspective, the current price is between the 10-day and 30-day moving averages, with the moving average system still in a bearish alignment.

Notably, there is significant divergence in the technical indicators. Multiple oscillation indicators such as the Stochastic Oscillator and CCI are in a neutral state, while the Williams %R indicator signals overbought conditions suggesting a sell, with the RSI at 47, indicating a neutral-to-weak region. However, the VR Volume Ratio Indicator shows 'oversold, possible bottom formation, buy,' and the Bull/Bear Power Indicator also shifted to 'buy,' reflecting increased buying support at lower levels. Nevertheless, MACD signals and Bollinger Bands remain at 'sell.' This divergence between trend indicators and some oscillators suggests that although the stock has rebounded recently, the medium-term structure has not completely escaped its weak pattern, and resistance may still be faced after the short-term rebound. A comprehensive summary signal from technical indicators is 'sell' with a strength of 8, indicating the market is currently in a tug-of-war phase between a rebound and mid-term pressure.

Regarding market news, recent fluctuations in Wuxi Bio's share price have mainly benefited from improved sentiment in the pharmaceutical outsourcing industry. According to mainland media reports, as global biopharmaceutical R&D investments gradually recover, expectations for order visibility in the CXO sector are improving. Wuxi Bio, as an industry leader, has seen its valuation retreat to a relatively reasonable level after experiencing significant adjustments earlier, attracting some funds to engage in short-term speculation.

In terms of sector performance, on April 1st, the Hong Kong-listed pharmaceutical outsourcing sector generally rebounded, with Wuxi Apptec rising about 5.28%, Pharmaron rising about 10.10%, and Tigermed rising about 5.89%, reflecting the concentration of capital in leading companies within the industry. Overall, after continuous adjustments, the technical rebound demand of the pharmaceutical outsourcing sector is gradually being released.

From a key position analysis, initial support below is at HKD 32.3, which is the low point of the recent adjustment area and also the first line of defense technically. If it breaks down, the next level of support will be at HKD 31.3, where the bottom of the previous consolidation zone offers strong support. Regarding resistance above, the first threshold is at HKD 36.9, near the 30-day moving average, and a breakout could aim towards HKD 38.4, where the 60-day moving average and previous high points during the decline are located. The overall probability of upward movement is 46%, indicating that although there are conditions for a short-term rebound, the range-bound rebound pattern will remain until the resistance at HKD 36.9 is broken.

In terms of warrant capital flows, according to the CBBC capital flow report as of March 31, Wuxi Bio showed significant volatility over the past five trading days. The aggregate net outflow for call warrants was HK$10,100, while put warrants recorded a net inflow of HK$2,200, resulting in a combined net outflow of HK$7,900 for all CBBCs. This reflects that bullish forces were weaker than bearish ones, with the market maintaining a generally cautious stance.

Looking at daily movements, call warrant capital flows were highly volatile: a net inflow of HK$9,900 on March 25, a significant net outflow of HK$35,700 on March 26, followed by another net outflow of HK$12,200 on March 27. On March 30 and 31, there was a rebound, with respective net inflows of HK$11,200 and HK$16,700, the latter being the highest single-day inflow during this period. This indicates a noticeable return of bullish capital after consecutive outflows, with market sentiment showing signs of recovery. In contrast, put warrant flows demonstrated a consistent small-scale inflow trend, with only a minor net outflow of HK$400 on March 30, while the other four trading days recorded net inflows totaling HK$2,200, reflecting continued modest bearish positioning and a defensive bearish stance towards future price movements.

Reviewing the performance of CBBC products, based on the products mentioned on March 30, underpinned by a cumulative 10.33% rise in the underlying stock over the following two trading days (March 31 to April 1), related products saw significant gains. Societe Generale’s call warrant (14297) surged 18% over the two days, effectively capturing the returns from the stock's rebound. BOCOM call warrant (17153) $BI-WUXI@EC2612A.C (17153.HK)$ also recorded an 18% gain, demonstrating stable performance. In terms of bull contracts, J.P. Morgan’s bull contract (56310) $JP#WUXI RC2708E.C (56310.HK)$ saw a cumulative increase of 74% over the two days, while UBS’s bull contract gained 70%, fully showcasing the high leverage characteristic of bull contracts in rebound scenarios. These four products delivered satisfactory returns during the stock rebound, illustrating that the appropriate use of call warrants and bull contracts can effectively amplify gains when share prices recover from lows.

In terms of product deployment, if investors believe that Wuxi Bio can hold above the support level of HK$32.3 and further challenge the resistance at HK$36.9, they may consider two call warrants. HSBC call warrant (22919) $HS-WUXI@EC2611A.C (22919.HK)$ with a strike price of HK$38.9 and effective leverage of 3.5 times, offers relatively ideal leverage and implied volatility levels. This product’s strike price is approximately 12.4% higher than the current underlying stock price, making it suitable for investors expecting the share price to gradually move toward the resistance zones of HK$36.9 and HK$38.4 amid the rebound. BOCOM call warrant (22714) $BI-WUXI@EC2611A.C (22714.HK)$ with a strike price of HK$38.9 and effective leverage of 3.4 times, also exhibits favorable leverage and implied volatility. Both call warrants have strike prices close to the resistance level at HK$38.4, reflecting alignment between product design and technical analysis resistance areas. If the share price successfully breaks through HK$36.9 and advances toward HK$38.4, these two products will directly benefit.

For investors favoring bull contracts, two bull contracts can be considered for deploying in a rebound scenario. UBS bull contract (59460) $UB#WUXI RC2708E.C (59460.HK)$ has a recovery price of HK$29, about 16.2% below the current underlying stock price, offering a relatively high margin of safety and effective leverage of 4.9 times—the highest actual leverage among similar products with lower premiums. This product suits investors expecting the share price to stabilize above HK$32.3 and continue rebounding; its higher leverage provides greater amplification of returns during a rebound. Societe Generale bull contract (66999) $SG#WUXI RC2606I.C (66999.HK)$The recovery price is also at HK$29, with an effective leverage of 5.2 times and the lowest premium among similar products, offering relatively higher actual leverage. Both have the same recovery price at the HK$29 level, far below the current support level of HK$32.3, indicating a lower risk of being forcibly recalled. This makes it suitable for investors who want to deploy a rebound with higher leverage. The low premium characteristic of Societe Generale's bull certificate means that the product price is less affected by market supply and demand fluctuations, and its pricing is closer to intrinsic value.

It should be noted that if the stock price fails to hold above the HK$32.3 support, it would indicate insufficient rebound momentum, and the holding pressure on the aforementioned call warrants and bull certificates will significantly increase. Investors should use HK$32.3 as an important observation point when deploying and strictly control their positions. Additionally, capital flow data shows continued modest inflows into put warrants by short sellers, reflecting market skepticism about the sustainability of the rebound, which is another factor to consider when positioning for a rebound.

Overall, Wuxi Bio is in a contradictory phase of 'technical rebound versus weak medium-term trend.' In the short term, the stock is more likely to fluctuate within the range of HK$32.3 to HK$36.9. The ideal approach is to wait for a clear breakout above the HK$36.9 resistance or a drop below the HK$32.3 support before making a move. If trading within this range, strict position control and reasonable stop-loss levels should be implemented.

Interactive Q&A:

Do you think Wuxi Bio's rebound can break through the HK$36.9 resistance?

A. It can break through; capital inflow and improved sector sentiment will drive the stock price higher.

B. Difficult to break through, weak mid-term trend will limit the upside

C. First, consolidate within the HK$32 to HK$36 range.

Feel free to share your thoughts in the comments section.

Disclaimer: This article does not constitute any investment advice. It is for reference only and should not be considered as investment advice. Market data, opinions, and analysis provided may change at any time without prior notice. We are not responsible for any loss or damage caused by reliance on the information in this article. Technical analysis only reflects whether certain technical conditions are met; asset performance should be evaluated comprehensively with additional information and decisions should not be based solely on this article. Past performance is not indicative of future results. Follow Jenny's Warrants for more professional insights on Hong Kong stocks. $Hang Seng Index (800000.HK)$$Hang Seng TECH Index (800700.HK)$$Hang Seng China Enterprises Index (800100.HK)$

#WuXi Biologics# #Technical Analysis# #Support Level# #Resistance Level# #Warrant# #Call Warrant# #Bullish Warrant# #Pharmaceutical Stocks# #Hong Kong Stock Warrants by Jenny#

262K Views